Clinical Trials Search Tool

A Donanemab Prevention Study in Participants with Alzheimer’s Disease

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 55-80

Enrollment Opens: 01-01-2022

Enrollment Closes: TBD


This is a preventative trial for those at risk for Alzheimer’s disease. The investigational product is an anti-amyloid antibody aimed at removing the amyloid plaques associated with Alzheimer’s disease. This study is also called the Trailblazer 3 Trial, and is sponsored by Eli Lilly and Company.


To Enroll: Call 503-476-9788 or schedule your free over-the-phone memory screen here:

Posted by: Center for Cognitive Health |